Immuneering Corp. Class A (IMRX)

Over the past six months, Immuneering's stock has been influenced by several events. In January 2026, positive 12-month overall survival data for atebimetinib in pancreatic cancer was announced, but the stock fell by 20%. In December 2025, the company secured alignment with the FDA and EMA for its Phase 3 trial and was added to the Nasdaq Biotechnology Index. November 2025 saw the release of Q3 financial results with an EPS of -$0.38 and a cash position of $227.6 million. In October 2025, Leerink Partners initiated coverage with an "Outperform" recommendation. September 2025 saw the completion of a $175 million Follow-on Equity Offering. The stock price on January 2, 2026, was $6.62 per share, a significant increase from $2.36 per share on January 6, 2025.

As a clinical-stage biotechnology company, Immuneering Corp. is primarily focused on research and development and does not yet have commercialized products generating revenue. Therefore, there is no readily available information or explicit indication of demand seasonality for Immuneering Corp.'s products and services. The company's financial performance is currently driven by investments in research and development and fundraising rather than product sales.

Immuneering Corporation is a clinical-stage oncology company focused on developing immunology solutions for oncologic and neurologic diseases, operating in the Biotechnology industry. They utilize their Disease Cancelling Technology platform for drug discovery, aiming to create transformative therapies for autoimmune disorders, infectious diseases, and cancer. Key product candidates include Atebimetinib, an oral MEK inhibitor planned for a Phase 3 trial in pancreatic cancer, and IMM-6-415, which aims for universal-MAPK activity and is in IND enabling studies. The pipeline also includes Trifecta MEK, RAS modulators, and other small molecule drug discovery programs.

Immuneering Corporation is headquartered in Cambridge, Massachusetts, United States. The information does not detail a broader geographic operational footprint or market reach beyond its research and development activities in the US.

Immuneering's brand reputation is characterized by a "Moderate Buy" consensus rating from Wall Street analysts. Positive clinical data, especially for atebimetinib in pancreatic cancer, contributes positively to its reputation. However, the stock's negative reaction to positive survival data in January 2026, possibly due to the Phase 3 trial timeline, indicates that investor sentiment is sensitive to development timelines. An earlier stock plunge in March 2024 followed Phase 1 data for IMM-1-104, as investors were not impressed by a lack of confirmed responses across different doses, leading to analyst downgrades.

Immuneering Corporation has a mixed ownership structure, including institutional, retail, and individual investors. Approximately 23.37% of the company's stock is owned by Institutional Investors, 9.41% by Insiders, and 67.23% by Public Companies and Individual Investors. Major institutional owners include Fmr Llc, Sanofi, Vanguard Group Inc, Price T Rowe Associates Inc /md/, ExodusPoint Capital Management, LP, Logos Global Management LP, Citadel Advisors Llc, BlackRock, Inc., Blue Owl Capital Holdings LP, HBM Healthcare Investments (Cayman) Ltd., The Vanguard Group, Inc., and T. Rowe Price Group, Inc. The CEO, Benjamin J. Zeskind, directly holds 5.0% of the total shares outstanding.